Iron reduction and sustained response to interferon-α therapy in patients with chronic hepatitis C: Results of an Italian multicenter randomized study

American Journal of Gastroenterology

Volumn 97, Issue 5, 2002, Pages 1204-1210

  Fargion, Silvia ^a,k   Fracanzani, Anna Ludovica ^a   Rossini, Angelo ^b   Borzio, Mauro ^c   Riggio, Oliviero ^d   Belloni, Giovanni ^e   Bissoli, Franco ^f   Ceriani, Roberto ^g   Ballarè, Marco ^h   Massari, Marco ⁱ   Trischitta, Caterina ^j   Fiore, Pierluigi ^d   Orlandi, Anna ^k   Morini, Lorenzo ^l   Mattioli, Michela ^a   Oldani, Silvia ^a   Cesana, Bruno ^k   Fiorelli, Gemino ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b Spedali Civili Brescia   (Italy)

^c FATEBENEFRATELLI HOSPITAL   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^f Ospedale di Legnano   (Italy)

^g HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^h Ospedale Di Novara   (Italy)

ⁱ Divisione Malattie Infettive   (Italy)

^j C/o OO RR S Marta e Villermosa   (Italy)

^k FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^l Ospedale di Magenta   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; GAMMA GLUTAMYLTRANSFERASE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRY WEIGHT; FEMALE; GENE MUTATION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; IRON BLOOD LEVEL; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PHLEBOTOMY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REDUCTION; TREATMENT OUTCOME; VIRUS VIRULENCE;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; IRON; LIVER; MALE; MIDDLE AGED; PHLEBOTOMY; TREATMENT OUTCOME;

EID: 19244382256     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(02)04061-3     Document Type: Article

References (31)

1. Natural history of hepatitis C
2. Clinical outcomes after transfusion-associated hepatitis C
3. The treatment of chronic viral hepatitis
4. Response to interferon therapy is influenced by iron content of the liver
5. Hepatic iron concentration as a predictor of response to interferon alpha therapy in chronic hepatitis C
6. Liver iron influences the response to interferon alpha therapy in chronic hepatitis C
7. Iron and chronic viral hepatitis
8. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatits C and excess hepatic iron
9. Iron stores, response to interferon therapy, and effects on iron depletion in chronic hepatitis C
10. Relationship between hepatic iron deposits and response to interferon in chronic hepatitis C
11. Factors predictive of a beneficial response to therapy of hepatitis C
12. Elevated serum iron predicts poor response to interferon treatment in patients with chronic HCV infection
13. Distribution of iron in the liver predicts the response of chronic hepatitis C infection to interferon therapy
14. A pilot randomized, controlled trial of the effect of iron depletion on long term response to alpha-interferon in patients with chronic hepatitis C
15. Iron reduction before and during interferon therapy of chronic hepatitis C. Results of a multicenter, randomized, controlled trial
16. Retreatment of hepatitis C interferon non-responders with larger doses of IFN with and without phlebotomy
17. The effect of iron depletion on long-term response to interferon in patients with chronic hepatitis C who previously did not respond to interferon therapy
18. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: A multicenter, prospective, randomized, controlled trial
19. Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis
20. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis
21. Measurement of liver iron concentration in needle biopsy specimens
22. High prevalence of His63Asp HFE mutations in Italian patients with porphyria cutanea tarda
23. Detection of hepatitis C virus by polymerase chain reaction and response to interferona therapy: Relationship to genotypes of hepatitis C virus
24. Hepatic iron contents and response to interferon-α in patients with chronic hepatitis C. Relationship to genotypes of hepatitis C virus
25. Liver biopsy is a useful predictor of response to interferon therapy in chronic hepatitis C
26. Threshold effect of liver iron content on hepatic inflammation and fibrosis in hepatitis B and C
27. Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C
28. Interfernon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitic C
29. Increase in hepatic iron stores following prolonged therapy with ribavirin in patients with chronic hepatitis C
30. Increased hepatic iron deposition resulting from treatment of chronic hepatitis C with ribavirin